Evidence mapPaperPMID 38884061Full record

ArticlePhenomics (Cham, Switzerland)2024

A Proactive Intervention Study in Metabolic Syndrome High-Risk Populations Using Phenome-Based Actionable P4 Medicine Strategy.

Qiongrong Huang, Zhiyuan Hu, Qiwen Zheng, Xuemei Mao, Wenxi Lv, Fei Wu, Dapeng Fu, Cuihong Lu, Changqing Zeng, Fei Wang and 3 more

Abstract read
In one paragraph

Article in Phenomics (Cham, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qiongrong Huang *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, CAS Center for Excellence in Nanoscience, Beijing, 100190 China.ORCID 0009-0004-5248-9597
Zhiyuan Hu *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, CAS Center for Excellence in Nanoscience, Beijing, 100190 China.ORCID 0000-0003-2212-0268
Qiwen Zheng *CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, 100101 China.ORCID 0000-0001-6921-6254
Xuemei MaoBeijing P4 Healthcare Institute, 316 Wanfeng Road, Beijing, 100161 China.ORCID 0009-0008-0017-7806
Wenxi LvBeijing P4 Healthcare Institute, 316 Wanfeng Road, Beijing, 100161 China.ORCID 0009-0006-0334-3158
Fei WuBeijing P4 Healthcare Institute, 316 Wanfeng Road, Beijing, 100161 China.ORCID 0000-0002-6713-0374
Dapeng FuBeijing Zhongguancun Hospital, No. 12, Zhongguancun South Road, Haidian District, Beijing, 100190 China.ORCID 0009-0002-9108-5849
Cuihong LuBeijing Zhongguancun Hospital, No. 12, Zhongguancun South Road, Haidian District, Beijing, 100190 China.ORCID 0009-0007-1905-7786
Changqing ZengCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, 100101 China.ORCID 0000-0002-0037-1771
Fei WangHealth Management Institute, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese People's Liberation Army (PLA) General Hospital, 28 Fuxing Road, Beijing, 100853 China.ORCID 0000-0001-9776-4792
Qiang ZengHealth Management Institute, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese People's Liberation Army (PLA) General Hospital, 28 Fuxing Road, Beijing, 100853 China.ORCID 0000-0002-4961-0171
Qiaojun FangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, CAS Center for Excellence in Nanoscience, Beijing, 100190 China.ORCID 0000-0002-2856-3281
Leroy HoodHealth Management Institute, The Second Medical Center, National Clinical Research Center for Geriatric Diseases, Chinese People's Liberation Army (PLA) General Hospital, 28 Fuxing Road, Beijing, 100853 China.ORCID 0000-0001-7158-3678

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of predictive, preventive, personalized, and participatory (P4) healthcare advocates proactive intervention, including dietary supplements and lifestyle interventions for chronic disease. Personal profiles include deep phenotypic data and genetic information, which are associated with chronic diseases, can guide proactive intervention. However, little is known about how to design an appropriate intervention mode to precisely intervene with personalized phenome-based data. Here, we report the results of a 3-month study on 350 individuals with metabolic syndrome high-risk that we named the Pioneer 350 Wellness project (P350). We examined: (1) longitudinal (two times) phenotypes covering blood lipids, blood glucose, homocysteine (HCY), and vitamin D Supplementary Information: The online version contains supplementary material available at 10.1007/s43657-023-00115-z.

Indexed as

Dietary supplementsExercisePersonalizedWellness

Identifiers

PMID38884061
PMCPMC11169348

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.